Payment overview · 2025
General Payments
$3,826.01
98 reported records · 20 companies
Healthcare provider profile · identity verified
Aaron Michael Bartek, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WAHOO, NE · NPI 1194292813
Verified facts
What the public records show
CMS Open Payments records show Aaron Michael Bartek, APRN received $3,826.01 in general payments during 2025 across 98 reported records.
TG Therapeutics, Inc. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bafiertam, Vumerity, Zeposia.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zeposia by this doctor in 2024.
Cycle Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Bafiertam as an associated drug or biological on 1343 records involving 850 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Bafiertam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $2,101.94 | 54.9% | 16 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $372.07 | 9.7% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $237.49 | 6.2% | 17 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $197.47 | 5.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.95 | 4.9% | 11 | 2025 |
| PIRAMAL CRITICAL CARE | Unresolved — no canonical attribution shown | $120.14 | 3.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.06 | 2.8% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.67 | 2.6% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $99.44 | 2.6% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $46.08 | 1.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.53 | 1.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.15 | 1.0% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.43 | 0.9% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $30.00 | 0.8% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $27.69 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.90 | 0.5% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.78 | 0.5% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.12 | 0.5% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $15.10 | 0.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.00 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,191.01 | 95 |
| Consulting Fee | $1,635.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $2,101.94 | 16 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $301.80 | 7 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $237.49 | 17 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $122.24 | 6 | 2025 |
Source payment records
|
|||||
| GABLOFEN Normalized: gablofen |
Drug | PIRAMAL CRITICAL CARE | $120.14 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $118.52 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $106.06 | 6 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $100.67 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.43 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.52 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $46.08 | 3 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $38.15 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Tyruko Normalized: tyruko |
Biological | Sandoz Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Bafiertam bafiertam |
2025 | Bafiertam | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Cycle Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Bafiertam open payments reported associated product |
CMS Open Payments — General Payments 1343 supporting records · 850 recipient NPIs · example record 1248898758 |
Bafiertam · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Baclofen | Baclofen | 101 | 28 |
| Gabapentin | Gabapentin | 67 | 14 |
| Teriflunomide | Teriflunomide | 67 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | suppressed |
| Kesimpta Pen | Ofatumumab | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Dalfampridine Er | Dalfampridine | 29 | suppressed |
| Vumerity | Diroximel Fumarate | 29 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Prednisone | Prednisone | 24 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 23 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Aubagio | Teriflunomide | 19 | suppressed |
| Bafiertam | Monomethyl Fumarate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 14 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,826.01 · 98 records | TG Therapeutics, Inc. | ACTHAR, AMPYRA, BOTOX, BRIUMVI, Bafiertam, Dysport, EMGALITY, GABLOFEN, KESIMPTA, KISUNLA, NUEDEXTA, NURTEC ODT, Ocrevus Zunovo, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, SYNCHROMEDII, TYSABRI, Tyruko, UBRELVY, VUMERITY, Xeomin, ZAVZPRET, ZEPOSIA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bafiertam play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error